Skip to content

Monopar Therapeutics Inc.

MNPR

CIK 0001645469

← back to feed
Revenue (TTM)
$0
Q1 Apr 2026
Net Income (TTM)
−$12.41M
+12.0% YoY Q1 Apr 2026
EPS Diluted (TTM)
—
Q1 Apr 2026
Gross Margin
—
Q1 Apr 2026
Operating Margin
—
Q1 Apr 2026
Net Margin
—
Q1 Apr 2026
Free Cash Flow (TTM)
—
Q1 Apr 2026
Cash
$52.54M
Q1 Apr 2026
Total Debt
—
Q1 Apr 2026
Shares Outstanding
6.7M sh
Q1 Apr 2026

Revenue & Net Income

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings